RLMD (STOCKS)
Relmada Therapeutics, Inc. Common Stock
$4.750000
+0.030000 (+0.64%)
Prev close: $4.720000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Sergio Traversa
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $508.28M
- Employees
- 17
- P/E (TTM)
- -5.11
- P/B (TTM)
- 2.44
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $3.21M |
| Operating Expenses | $65.13M |
| Research and Development | $28.59M |
| Other Operating Expenses | $36.54M |
| Operating Income/Loss | -$65.13M |
| Income/Loss From Continuing Operations After Tax | -$61.93M |
| Income/Loss From Continuing Operations Before Tax | -$61.93M |
| Net Income/Loss | -$61.93M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$61.93M |
| Net Income/Loss Available To Common Stockholders, Basic | -$61.93M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.91 |
| Diluted Earnings Per Share | -$0.91 |
| Basic Average Shares | 139,724,587 |
| Diluted Average Shares | 139,724,587 |
| Assets | $219.06M |
| Current Assets | $219.04M |
| Prepaid Expenses | $1.30M |
| Other Current Assets | $217.74M |
| Noncurrent Assets | $19.50K |
| Liabilities | $12.50M |
| Current Liabilities | $7.42M |
| Accounts Payable | $2.41M |
| Other Current Liabilities | $5.01M |
| Noncurrent Liabilities | $5.08M |
| Equity | $206.56M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $206.56M |
| Liabilities And Equity | $219.06M |
| Net Cash Flow From Operating Activities | -$45.99M |
| Net Cash Flow From Operating Activities, Continuing | -$45.99M |
| Net Cash Flow From Investing Activities | -$187.82M |
| Net Cash Flow From Investing Activities, Continuing | -$187.82M |
| Net Cash Flow From Financing Activities | $243.79M |
| Net Cash Flow From Financing Activities, Continuing | $243.79M |
| Net Cash Flow | $9.98M |
| Net Cash Flow, Continuing | $9.98M |
| Comprehensive Income/Loss | -$61.93M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$61.93M |
| Other Comprehensive Income/Loss | $0.00 |